The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Molecular Characterisation Of Host Cell Targets Of Human Pathogenic Viruses And Evaluating Their Potential As Novel Therapeutic Targets.
Funder
National Health and Medical Research Council
Funding Amount
$307,946.00
Summary
There are currently no therapeutics to treat victims of Hendra, Nipah or Rabies virus infections, which account for > 50,000 deaths/yr worldwide. Through not fully understood mechanisms, these viruses affect the functions of specific cellular proteins in order to inhibit the host immune system, a process essential to their pathogenicity. We aim to characterise the mechanisms underlying viral inhibition of host immunity and evaluate their potential as novel targets to develop urgently needed t ....There are currently no therapeutics to treat victims of Hendra, Nipah or Rabies virus infections, which account for > 50,000 deaths/yr worldwide. Through not fully understood mechanisms, these viruses affect the functions of specific cellular proteins in order to inhibit the host immune system, a process essential to their pathogenicity. We aim to characterise the mechanisms underlying viral inhibition of host immunity and evaluate their potential as novel targets to develop urgently needed therapeutics against these deadly pathogens.Read moreRead less
The Role Of Endocannabinoids In Chronic Hepatitis C
Funder
National Health and Medical Research Council
Funding Amount
$563,002.00
Summary
Hormones related to cannabis help to regulate fat stores in the human body. CB1 antagonists are a new class of drugs that block these hormones and are being tested for the treatment of obesity and fatty liver. We discovered that Hepatitis C makes the liver more sensitive to these hormones, helping the hepatitis C virus to replicate. This project will determine the mechanisms by which CB1 antagonists prevent hepatitis C virus replication and their potential as a novel therapy for this disease.
Eliminating HCV: Statistical Modelling And Health Economic Evaluation In The New DAA Era
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
While new generation hepatitis C virus (HCV) treatments are highly efficacious, their high cost means multi-pronged approaches will be needed to reach elimination targets. This project will use statistical and mathematical modelling to inform real world health economic evaluations determine the most cost-effective response. This will inform health policy in Australia and globally.
Improved Treatment Of Congenital Cytomegalovirus Disease Through Study Of Placental Models Of Pathogenesis
Funder
National Health and Medical Research Council
Funding Amount
$674,918.00
Summary
Congenital CMV is the second most common cause of fetal malformation in Australia, and yet most pregnant mothers do not know about it, nor how to prevent congenital CMV in their baby. It is a viral infection that can severely damage the unborn baby. Our research aims to find more about how the virus damages the baby, and whether antiviral drugs are useful in reducing infection of the baby, and also reducing damage to the baby from such infection. If successful, these studies will be the basis fo ....Congenital CMV is the second most common cause of fetal malformation in Australia, and yet most pregnant mothers do not know about it, nor how to prevent congenital CMV in their baby. It is a viral infection that can severely damage the unborn baby. Our research aims to find more about how the virus damages the baby, and whether antiviral drugs are useful in reducing infection of the baby, and also reducing damage to the baby from such infection. If successful, these studies will be the basis for clinical trials in pregnant women.Read moreRead less
EEF1A1 Is Critical For HIV-1 Reverse Transcription And Replication
Funder
National Health and Medical Research Council
Funding Amount
$521,429.00
Summary
The project will investigate interaction between the AIDS virus, HIV-1, and the human cell it grows in specifically focusing on a human protein called eEF1A. Our research shows eEF1A is required for HIV-1 growth by regulating a step in the virus life cycle called reverse transcription. The goal of this project is investigate how interaction with eEF1A helps HIV-1 reverse transcription and to find drugs that block HIV-1 interaction with eEF1A.
Dengue viruses are transmitted by mosquitoes and cause major epidemics in more than 100 countries in tropical and subtropical regions. Infection with Dengue viruses cause Dengue fever or its more severe and sometimes fatal form, Dengue hemmorrhagic fever-Dengue shock syndrome (DHF-DSS). Up to 100 million people are infected annually making Dengue virus one of the most important and frequent mosquito-borne viral diseases worldwide. Over the past two decades, the incidence of Dengue virus infectio ....Dengue viruses are transmitted by mosquitoes and cause major epidemics in more than 100 countries in tropical and subtropical regions. Infection with Dengue viruses cause Dengue fever or its more severe and sometimes fatal form, Dengue hemmorrhagic fever-Dengue shock syndrome (DHF-DSS). Up to 100 million people are infected annually making Dengue virus one of the most important and frequent mosquito-borne viral diseases worldwide. Over the past two decades, the incidence of Dengue virus infection has increased steadily. More than 40% of the world's population is at risk of infection and this number is expected to increase as more people travel. This proposal focuses on the way dengue virus enters cells, specifically the mechanism used by viral proteins to mediate fusion of the viral membrane with that of the host cell. A clearer understanding of the molecular basis of this process should provide potential targets for new drugs that can bind and block this process. In addition, we will also use this information in the design and generation of new vaccine candidates.Read moreRead less
Targeting Novel Sites On Reverse Transcriptase For HIV Treatment And Prevention
Funder
National Health and Medical Research Council
Funding Amount
$978,994.00
Summary
HIV/AIDS remains a major global threat with 37 million individuals living with HIV in 2014. Antiretroviral drugs have transformed HIV from a death sentence into a chronic disease. Public health organisations recommend dramatic scale up of drugs for HIV treatment and prevention. However, a major threat is that drug options will be exhausted due to drug resistance and toxicity. The major aim of this study is to undertake fundamental studies to advance the development of a new HIV drug class.
This research draws together my expertise in medicinal chemistry, biochemistry, pharmacology and virology to design and develop new compounds that we can use to interrogate and regulate human and viral proteins that cause disease. Protein, cell and animal studies relevant to major 21st century health burdens (such as inflammatory, infectious and metabolic diseases, cancer, pain and viral infections) will provide important new information on mechanisms of disease development and drug action.
Hepatitis C virus is a major medical problem in Australia and many other parts of the world. The viruses causes a persistent infection in most infected individuals that results in serious liver disease and liver cancer in a proportion of patients. Treatment is only possible for a small percentage of patients and many patients are infected with viruses which are resistant to the best contemporary treatment regimens. The aim of this project is to develop systems which will result in the assembly o ....Hepatitis C virus is a major medical problem in Australia and many other parts of the world. The viruses causes a persistent infection in most infected individuals that results in serious liver disease and liver cancer in a proportion of patients. Treatment is only possible for a small percentage of patients and many patients are infected with viruses which are resistant to the best contemporary treatment regimens. The aim of this project is to develop systems which will result in the assembly of virus particles which can be used to examine the efficacy of potential antiviral agents, either in the test tube or by infecting an animal model. In particular, we will examine the contribution of a small viral protein, p7, on virus assembly and secretion from the infected cell. Recent data suggests that p7 can function to help release virus from the infected cell and a number of inhibitors of p7 function have been described. We will then use the systems which we develop to determine if these inhibitors can inhibit virus replication in the test tube and in animal models.Read moreRead less
This Practitioner Fellowship will support studies that will contribute directly to the efforts to eliminate HCV infection from Australia. The research program aims to reduce transmission of HCV infection by evaluating the best models of care for i) engaging and treating high risk individuals with HCV infection, including people who inject drugs and prisoners, ii) preventing reinfection with HCV, and iii) re-treatment of individuals who fail treatment due to drug resistance.